Small molecular compounds that can pass through the blood–brain barrier, enter the cells, and bind to intracellular aggregates of abnormal proteins would be promising candidates for pharmacotherapy of neurodegenerative diseases by promoting clearance of pathological TDP-43 proteins, e.g., by activating degradation or protein quality-control systems. The gene discussed is TARDBP; the disease is neurodegenerative disease.